알지노믹스

476830KOSDAQ자연과학 및 공학 연구개발업

53.5 / 100

Reference Date: 2026-07-24

Financial Score20.0 / 40

News Sentiment20.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 68.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aljonoomics is a biotech company that develops new drugs using platform technology, leveraging RNA trans-splicing ribozyme to target and replace specific RNA sequences with therapeutic genes. The company generates revenue through technology licensing and focuses on developing gene therapy treatments for genetic diseases and cancer, including hepatocellular carcinoma.

Number of Employees

39people

Average Salary

193.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

13.53Industry Average 2.520.0Point

5.4x industry avg (risky)

ROE

—Industry Average -32.093.5Point

Debt Ratio

1.62Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.0 / 3

Avg ▲1.8% (2-year basis)

ROE Trend

2.0 / 4

Detailed News Sentiment

18 totalPositive 17Neutral 1Negative 0Average Sentiment Score 81.9

Positive
알지노믹스, 美 일라이릴리서 난청치료제 연구비 추가 수령
알지노믹스는 일라이릴리와의 난청 치료제 공동연구에서 추가 연구비 확보로 기술 개발에 대한 긍정적 투자를 받았다.
Positive
릴리가 연구비 또 보냈다…알지노믹스, 유전성 난청 공동연구 지속
알지노믹스는 글로벌 제약사 릴리와의 유전성 난청 치료제 공동연구로 추가 연구비를 확보하여 개발 진행에 긍정적 영향을 받고 있다.
Positive
로킷헬스케어 자회사, 역노화 플랫폼 특허 5건 출원…장기 재생 기술.....
로킷제노믹스의 특허 출원으로 알지노믹스 관련 기술 혁신 기대

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 28,400Won52-week high 236,00052-week low 25,850

1-month return0.0Point

1m -68.55% (strong drop)

Volume trend2.0Point

Volume flat

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10